Navigation Links
Bayer's Investigational Riociguat Granted U.S. FDA Priority Review for Pulmonary Arterial Hypertension and Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
Date:4/7/2013

WAYNE, N.J., April 8, 2013 /PRNewswire/ -- Bayer HealthCare announced today that the New Drug Application (NDA) for its oral investigational compound riociguat has been accepted for filing and granted priority review by the U.S. Food and Drug Administration (FDA) for the treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or with persistent or recurrent CTEPH after pulmonary endarterectomy (PEA) and pulmonary arterial hypertension (PAH).

Both CTEPH and PAH are life-threatening diseases.  CTEPH is a form of pulmonary hypertension in which blood clots and thromboembolic occlusion of pulmonary vessels leads to increased pressure in the pulmonary arteries.  PAH is a disease characterized by elevated pressure in the pulmonary arteries.

"We are pleased that the FDA has granted priority review of the riociguat NDA for two distinct forms of pulmonary hypertension," said Pamela A. Cyrus , MD, Vice President and Head of U.S. Medical Affairs, Bayer HealthCare Pharmaceuticals. "This milestone reinforces our commitment to advancing treatment options for cardio-pulmonary diseases, and brings us one step closer to potentially providing the first pharmacological treatment for inoperable or persistent/recurrent CTEPH and a new treatment option for PAH."

The FDA grants priority review to medicines that provide a treatment where little or no adequate therapy exists. Under the Prescription Drug User Fee Act (PDUFA), the FDA aims to complete its review within six months of the 60-day filing receipt of the NDA submission (eight months total), rather than the standard 12-month review cycle.

The NDA submission is supported by data from two global Phase III studies of riociguat CHEST-1 and PATENT-1. Data from these two studies were presented in October 2012 at CHEST, the annual meeting of the American College of Chest Physicians (ACCP). Both Phase III studies on ri
'/>"/>

SOURCE Bayer HealthCare
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013
2. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
3. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
4. Genocea Publishes Preclinical Data For Investigational Vaccine Candidate For HSV-2
5. Noven Announces FDA Advisory Committee Vote on Investigational Low-Dose Mesylate Salt of Paroxetine (LDMP) for Vasomotor Symptoms Associated with Menopause
6. Scioderms Investigational New Drug (IND) Application for SD-101 for Treatment of Epidermolysis Bullosa (EB) Allowed by the FDA
7. BHR Pharma Investigational Traumatic Brain Injury Treatment Receives European Medicines Agency Orphan Medicinal Product Designation
8. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
9. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
10. FDA Accepts Novens NDA For An Investigational Nonhormonal Therapy For Menopausal Vasomotor Symptoms
11. Healthpoint Biotherapeutics Initiates Phase III Study of Unique Investigational Cell-Based Therapy for Venous Leg Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014  The BioFusionary Corporation, Inc. (TBC), ... proprietary electromagnetic induction platform with aesthetic and surgical ... under which TBC will merge with ... an all-stock transaction. Upon completion of ... the Australian Stock Exchange under the code COT. ...
(Date:7/29/2014)... 29, 2014 Today, Frost & Sullivan ... Sullivan Best Practices Award for Customer Value Leadership. ... platform that connects digital health application developers, medical ... pharmaceutical companies, prevention and wellness companies, population health ... Each year, Frost & Sullivan presents this award ...
(Date:7/29/2014)... --  Health 2.0 announces Bernard Tyson , CEO ... Eric Topol , Patrick Soon-Shiong , and Samsung,s President ... Annual Fall Conference this coming Sept. 21-24 in ... is set to host the very first Wearable Tech Fashion ... Consumer Tech & Wearables: Powering Healthy Lifestyles. The panel ...
Breaking Medicine Technology:The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited 2The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited 3Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 2Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 3Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 4Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 2Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 3
(Date:7/29/2014)... According to an article in the Daily ... a 52 year old woman in India. The surgery took ... had no idea that she had such a large tumor ... for years, but did not connect it to a possible ... the massive uterine fibroid after Latha was admitted for heavy ...
(Date:7/29/2014)... Little Rock, AR (PRWEB) July 29, 2014 ... S.Res.518 , a resolution declaring the week of October ... the value of case management in improving healthcare outcomes ... Pryor (D-AR) and Senator John Boozman (R-AR), with support ... American Case Management Association to honor case management professionals ...
(Date:7/29/2014)... Bethesda, Maryland (PRWEB) July 29, 2014 ... has been named a 2014 ASAE Power of ... Flu-Focused," a public awareness campaign to encourage everyone age ... annually. , ASAE recognized NFID for its power ... drive awareness and action among consumers and professionals about ...
(Date:7/29/2014)... Award-winning inventor Michael Croix has launched an Indiegogo campaign for ... embarrassing odors in the office. PoofPad is a discrete bag ... desk drawer. This compact packaging is designed for ease of ... the pad and poof away! , “We’ve all been there. ... appears out of nowhere. It’s embarrassing and unpleasant for everyone ...
(Date:7/29/2014)... Recognition, and Control (A.R.C.) Against Depression" was written by ... men to heed the call to self-help.. , Ray J. ... no job, leaving Raymond with a mortgage payment he could ... the emotional disturbance was so great that they put him ... to the root of his problems. , Raynond says, “Even ...
Breaking Medicine News(10 mins):Health News:World’s Largest Uterine Fibroid Removed from Patient 2Health News:World’s Largest Uterine Fibroid Removed from Patient 3Health News:CMSA Supports National Case Management Week Resolution Introduced in US Senate 2Health News:National Foundation for Infectious Diseases Receives Top ASAE Honors for Keeping the Nation Flu-Focused 2Health News:Award-Winning Inventor Michael Croix Launches an Indiegogo Campaign for PoofPad 2Health News:Award-Winning Inventor Michael Croix Launches an Indiegogo Campaign for PoofPad 3Health News:SBPRA Announces the Release of Its Newest Title, "Acceptance, Recognition, and Control (A.R.C.) Against Depression" 2
... HIV-positive head and neck cancer patients respond well to ... non-HIV-positive patients, despite prior reports to the contrary, according ... International Journal of Radiation OncologyBiologyPhysics , an official ... , Patients with HIV have a significantly higher risk ...
... A new program designed to create comprehensive, integrated, whole-person ... a $3.9 million grant from the Colorado Health Foundation. ... in the Department of Family Medicine at the University of ... and national leaders from the mental health, substance use, and ...
... , TUESDAY, Jan. 18 (HealthDay News) -- Seeing ... smokers, brains to plan the same motions, new research shows. ... brain activity in 17 smokers and 17 nonsmokers as they ... scenes, the smokers, brains showed increased activity in areas involved ...
... TORONTO, ON Adult children of divorce are more likely to ... suggests new research from the University of Toronto , In ... Psychiatry Research, investigators examined gender specific differences among a ... divorce before the age of 18. The study found that ...
... By Jenifer Goodwin HealthDay Reporter , ... reports from patients suggest that a controversial treatment for ... but many physicians remain highly skeptical of the ... Paolo Zamboni, a vascular surgeon from Italy, published an ...
... Rochester Institute of Technology indicates that the incidence of ... more than 25 percent higher among deaf and hard-of-hearing ... a direct correlation between childhood maltreatment and higher rates ... The study, which was presented at the 2010 ...
Cached Medicine News:Health News:HIV-positive head and neck cancer patients benefit from radiation therapy 2Health News:New program targeting whole-person health care gets major grant 2Health News:Smoking Scenes in Movies Light Up Smokers' Brains 2Health News:Parental divorce linked to suicidal thoughts 2Health News:Vein-Opening Treatment for MS Stirs Controversy 2Health News:Vein-Opening Treatment for MS Stirs Controversy 3Health News:Vein-Opening Treatment for MS Stirs Controversy 4Health News:Study: Abuse rates higher among deaf and hard-of-hearing children compared with hearing youths 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: